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Abstract
Background: Novel oral anticoagulation (NOAC) has been introduced in recent years, but data on use in atrial
fibrillation (AF) in primary care setting is scarce. In Germany, General Practitioners are free to choose type of oral
anticoagulation (OAC) in AF. Our aim was to explore changes in prescription-rates of OAC in German primary care
before and after introduction of NOAC on the market.
Methods: Data of a representative morbidity registration project in primary care in Germany (CONTENT) were
analysed. Patients with AF in 2011 or 2014 were included (before and after broad market authorization of NOAC,
respectively). We defined three independent groups: patients from 2011 without follow-up (group A), patients from
2014 but without previous record in 2011 (group B) and patients with AF and records in 2011 and 2014 (group C).
Results: 2642 patients were included. Group A (n = 804) and B (n = 755) were comparable regarding patient
characteristics. 87.3% of group A and 84.8% of group B had CHA2DS2-VASc-Score ≥ 2, indicating a need for oral
anticoagulation (OAC). Prescription of OAC increased from 23.1% (n = 186) to 42.8% (n = 323, p < .01) with stable use
of vitamin-k-antagonist (22.6–24.9%). NOAC increased from 0.6 to 19.2% (p < .01). Monotherapy with Acetylsalicylic
acid (ASA) decreased from 15.3% (n = 123) to 8.2% (n = 62, p < .01). In group C (n = 1083), OAC increased from 35.3
to 55.4% (p < .01), with stable prescription rate of vitamin-k-antagonist (34.4–35.7%). NOAC increased from 0.9 to 21.
5% (p < .01).
Conclusions: In summary, our study showed a significant increase of OAC over time, which is fostered by the use
of NOAC but with a stable rate of VKA and a sharp decrease of ASA. Patients on VKA are rarely switched to NOAC,
but new patients with AF are more likely to receive NOAC.
Keywords: Atrial fibrillation, Stroke prevention, Oral anticoagulation, Vitamin K antagonists, Novel oral
anticoagulants
* Correspondence: simon.schwill@med.uni-heidelberg.de
1Department of General Practice and Health Services Research, University
Hospital Heidelberg, Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schwill et al. BMC Family Practice  (2018) 19:115 
https://doi.org/10.1186/s12875-018-0796-4
Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia, with an estimated prevalence of 1.5 to 2% of
the general population, which is increasing worldwide,
driven by an ageing population [1–3]. Nearly 10% of people
above 75 years suffer from AF [4]. Patients have an almost
fivefold higher risk of stroke [5] and mortality is up to 2.5
times higher compared with age-matched individuals [2].
Regardless of causal treatment, prophylaxis of stroke by
use of oral anticoagulation (OAC) was shown to reduce
risk of stroke and therefore is recommend in patients with
AF by international guidelines [6, 7]. The CHA2DS2--
VASc-Score has been recommended for risk stratification
[6–8]. For decades vitamin-K antagonists (VKA) had been
the only OAC in AF, accompanied by prescription of
acetylsalicylic acid (ASA), which is no longer recom-
mended [6, 7]. In recent years novel-oral-anticoagulants
(NOAC) such as Apixaban, Dabigatran, Edoxaban and
Rivaroxaban offered an alternative OAC to prevent stroke
in non-valvular AF. Use of NOAC is increasing and re-
cently updated guidelines on AF by the European Society
of Cardiology advocate use of NOAC over VKA [6]. Clin-
ical guidelines on AF for primary care physicians present
NOAC as a valid option, but do not necessarily recom-
mend changing patients from VKA to NOAC [9].Data on
use of (N)OAC in AF in routine primary care setting is
scarce [10–14]. In Germany, NOAC were licensed for the
indication of oral anticoagulation for the prevention of
stroke in non-valvular atrial fibrillation between Novem-
ber 2011 and June 2015: Dabigatran in 11 /2011, Rivaroxa-
ban in 12/2011, Apixaban in 12/2012 and Edoxaban in
06/2015 [15–18]. The aims of this study were to docu-
ment changes in prescription-rates of OAC (VKA and
NOAC) in primary care patients with AF in Germany be-
fore and after introduction of NOAC on the market, and
to explore whether known patients with AF were switched
onto NOAC.
Methods
Study design
We performed a retrospective epidemiological study in
primary care practices including a cross-sectional com-
parison of two independent samples and a cross-sectional
comparison of same patients at two points of time.
Setting
Data were derived from the CONTinuous-morbidity-
registration-Epidemiologic-NeTwork (CONTENT) in
South-Germany, which started in 2005 [19]. A total of
43 general practices were involved in this study. CON-
TENT provides representative data in terms of social, eth-
nic and economic backgrounds as well as urban, suburban
and rural areas. The quality of data is high due to constant
education of participating teams as well as continuous
feedback on recording quality to participating physicians.
Sample
In 2016, data of CONTENT starting in 2005 up to
31.12.2014 was included in the study and analysed retro-
spectively. We performed a before and after comparison
on the prescription of OAC, which compared data from
2011, when there was little experience with NOAC and
data from 2014, when Apixaban, Dabigatran and Rivar-
oxaban were broadly available. Edoxaban was not li-
censed in Germany in 2014. Out of all patients with
diagnosed AF (ICD I48.0) we included patients with AF
from 01.01.2011–31.12.2011 or 01.01.2014–31.12.2014.
Afterwards, we, defined three independent groups: pa-
tients with AF in 2011 but without follow-up in
2014(group A), patients with AF in 2014 but without
previous record in 2011 (group B) and patients with AF
and records in 2011 and 2014 (group C). Difference be-
tween groups A and B was related to newly diagnosed
AF, mortality and patient change of practice. Patients of
group C were not included in other groups neither A
nor B.
Measures
Relevant data were extracted from the CONTENT data-
base. For each patient age, gender as well as prescription
of medication, diagnoses and specialist referrals were
determined. Age was calculated from the year of birth.
Gender and age were used for measurement of
CHA2DS2-VASc-Score. Diagnoses were given as ICD-10
codes. Prescriptions were given as ATC-codes (Anatom-
ical Therapeutical Classification for medication, World
Health Organization). Secondly, prescriptions were ana-
lysed for VKA [Phenprocoumon =ATC-B01AA04] and
NOAC [Apixaban = ATC-B01AX08, Dabigatran = ATC--
B01AE07, Rivaroxaban = ATC-B01AX06] and ASA [acet-
ylsalicylic-acid = ATC-B01AC06]. We extracted diagnoses
needed for the CHA2DS2-VASc-Score: Congestive heart
failure (I50.*), Hypertension (I10.*) Diabetes (E10.-E11.*,
E14.*), Stroke (I63.*) and Vascular disease (I70.*). At time
of study CHA2DS2-VASc-Score ≥ 2 indicated OAC in pa-
tients with AF7. If data of hypertension or diabetes were
not encoded, prescription of an antidiabetic [ATC-A10] or
antihypertensive [angiotensin-converting-enzyme-inhibi-
tor = ATC-C09AA, Angiotensin-II-receptor-antagonists =
ATC-C09CA, Nifedipine = ATC-C08CA05, Hydrochloro-
thiazide = ATC-C03AA03] medication was accepted
instead.
To address potential contraindications we extracted diag-
noses renal insufficiency (N17.*-N19.*), coagulopathy
(D68.-D69.*), intracranial bleeding (I60.-I62.*, S06.4-S06.6.*,
S06.9), epistaxis (R04.0-R04.2), gastrointestinal bleeding
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(K92.0-K92.2, K62.5) and stroke (I63.-I64.*). We recorded
specialist referrals only to cardiologists.
Data analysis
Patient-characteristics were summarized in terms of fre-
quencies of categories, means with standard deviation and
medians with interquartile range for continuous variables.
Differences between independent groups A and B were
tested in Chi-squared-tests for frequencies, Fishers exact
test, t-tests for independent samples or MannWhitney-
U-tests for continuous data, dependent on data distribu-
tion. Changes over time (group C) were analysed with
McNemar’s-tests for frequencies and t-tests for dependent
samples or Wilcoxon-signed-rank-tests for continuous
data, dependent on data distribution. P-values < 0.05 were
considered to indicate statistical significance. Due to the ex-
ploratory character of the analysis, there was no correction
for multiple testing. All analyses were performed with IBM
SPSS version 21.0.
Results
Patient characteristics
Total number of patient in CONTENT in 2011 was n =
145,461 (point-prevalence of AF on 31.12.2011: 1.51%),
in 2014 n = 207,253 (point-prevalence of AF on
31.12.2014: 1.85%).In total, data of n = 2642 patients
from 43 general practices was obtained in this study. We
included n = 804 in Group A, n = 755 in Group B and n
= 1083 in Group C. In two-sample comparison, pre-
sented in Table 1, groups A and B did not differ regard-
ing sex or comorbidities, but group B was younger than
group A (p < 0.01). Number of patients > 75 years, con-
tributing to CHA2DS2-VASc-Score twice, was 66.3% in
group A (n = 533) which was comparable to 61.9% in
group B (n = 467). 87.3% of patients in group A (n = 702)
and 84.8% of patients in group B (n = 640) presented
with CHA2DS2-VASc-Score ≥ 2, which indicated OAC at
time of the study (p = n.s.).
Group C included n = 1083 patients (Table 2), of whom
51.9% were above 75 years in 2011 (n = 562) and 64.4% in
2014 (n = 697). Percentage of patients with CHA2DS2--
VASc-Score ≥ 2 increased from 81.6% (n = 884) to 83.8%
(n = 908, p < .01). 91% of patients with diagnosed AF pre-
sented with at least one additional diagnosis, such as renal
insufficiency (n = 1003).
Prescription of oral-anticoagulation
Two-sample comparison revealed an increase of pre-
scription of OAC from 23.1% in 2011 (n = 186) to 42.8%
in 2014 (n = 323, p < .01). Prescription-rate of VKA
remained stable (22.6%, n = 182 and 24.9%, n = 188). Pre-
scription of NOAC increased from 0.6% (n = 5) to 19.2%
(n = 145, p < .01), whereas monotherapy with ASA de-
creased from 15.3% (n = 123) to 8.2% (n = 62, p < .01).
The majority of patients with NOAC in 2014 received
Rivaroxaban (84.8%, n = 121) compared to Dabigatran
(9.6%, n = 14) and Apixaban (6.9%, n = 10). In 2014, car-
diologists were involved more often compared with 2011
(15.5%, n = 125versus 21.9%, n = 165, p < .01).
In group C (involving longitudinal comparison, n = 1083),
prescription of OAC increased from 35.3% (n = 382) to
55.4% (n = 600, p < .01) with similar prescription rate of
VKA (34.4%, n = 373 and 35.7%, n = 387). Mean annual
prescriptions per patient increased from 19.3 to 22.4 (p
< .01). Prescription of NOAC in group C increased from
0.9 to 21.5% (p < .01). Prescription of ASA decreased over
time (2011:12.6%, n = 136, 2014:9.0%, n = 97, p < .01). 11.9%
(n = 44) of patients with VKA were switched to NOAC and
in 19.9% OAC (n = 74) was discontinued completely. In
2011, 9 patients received a NOAC, of which 4 were
stopped until 2014 and one patient was switched to VKA.
11.9% (n = 44) of patients with VKA were switched to
NOAC. In 2014, majority of patients with AF and OAC
received VKA: Group B: 56% n = 188/333, Group C:
62.5% n = 387/619.
In group C, 22.6–24.2% of patients attended a cardiolo-
gist but involvement of cardiologists did not significantly
change over time (2011: 22.6%, 2014: 24.2%, p < .32). If
cardiologists were involved, prescription of OAC in-
creased over time from 51.6% in 2011 to 67.2% of patients
in 2014 (p < .01).
Discussion
In patients with recorded AF in German primary care
there was in increase in prescription-rate for OAC be-
tween 2011 and 2014: A cross-sectional comparison re-
vealed that in 2014 42.8% (n = 323) of patients with AF
received OAC compared to 23.1% (n = 186) in 2011. A
longitudinal comparison (group C) showed an increase
of OAC in AF from 35.3% (n = 383) to 55.4% (n = 600).
This increase in prescription-rate was mainly due to new
prescription of NOAC, while prescription-rate of VKA
remained stable. In longitudinal comparison (group C)
use of NOAC increased to 21.4% (n = 232) of patients
with AF in 2014, with Rivaroxaban as most frequently
prescribed. In 2014, cardiologists were involved in about
25% of patients (Group B: 21.9% (n = 165) and Group C:
24.2% (n = 262) and their involvement increased the like-
lihood of OAC prescribing. However, analysis showed no
difference in cardiologists preference between VKA and
NOAC and in 2014 majority of patients with OAC in
AF still received VKA (Group B: 56% n = 188/333,
Group C: 62.5% n = 387/619). Our analysis showed that
patients were rarely switched from VKA to NOAC but
were more likely to receive NOAC if diagnosed newly.
Interestingly, over 80% of patients with AF (group A
87.3%, group B 84.8%, group C 81.6%/83.8%) presented
with CHADS-VasC Score ≥ 2 indicating OAC (at time of
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study). High percentage might be explained by the age,
as in our study about two third of patients were 75 years
of age or higher, scoring 2 within the CHA2DS2-VASc--
Score, and thereby had a formal indication for OAC at
time of the study. However, this represents the pop-
ulation in primary care.Recently updated guidelines on
AF postulate evidence that OAC can prevent majority of
ischemic strokes in AF and prolong life [6]. Although
our findings suggest suboptimal prescribing-rates of
OAC, they should be interpreted carefully. Patient
populations in clinical trials of OAC differ regarding age,
sex and co-morbidities from those treated in primary
care [20, 21].
The benefit-risk-ratio of OAC and NOAC more particu-
larly, may be less positive in primary care patients com-
pared to patients in cardiology trials. In routine data, we
miss documentation of reasons for not-prescribing OAC
such as increased bleeding risk, alcohol-abuse, liver-failure
or uncontrolled hypertension (which could not be
accessed). Qualitative studies on prescribing OAC in
Table 1 Patient characteristics comparing 2011 and 2014 independently
GROUP A (2011) GROUP B (2014) p-value
patients (n) total 804 755
gender (%) male 374 (46.5%) 388 (51.4%) .06a
female 429 (53.4%) 367 (48.6%)
undetermined 1 (0.1%) 0
age (years) Median (IQR) 79 (71–86) 77 (70–83) <.01b
Min – Max 19–99 18–103
< 65 92 (11.4%) 118 (15.6%)
65–74 179 (22.3%) 170 (22.5%)
≥75 533 (66.3%) 467 (61.9%)
additional diagnosis at least 1 additional 750 (93.3%) 724 (95.9%) .02a
renal insufficiency 54 (6.7%) 55 (7.3%) .66a
coagulopathy 13 (1.6%) 17 (2.3%) .36a
intracranial bleeding 8 (1.0%) 6 (0.8%) .68a
epistaxis 7 (0.9%) 10 (1.3%) .39a
gastrointestinal bleeding 15 (1.9%) 12 (1.6%) .68a
stroke 43 (5.3%) 34 (4.5%) .44a
CHA2DS2-VASC: 0 48 (6.0%) 56 (7.4%) .34
a
1 54 (6.7%) 59 (7.8%)
≥2 702 (87.3%) 640 (84.8%)
prescriptions (per year) patients with at least 1 prescription 684 (85.1%) 677 (89.7%) <.01a
Md (IQR) 12 (5–25) 15 (6–24) .31b
Min - Max 1–123 1–123
all patients .02b
Md (IQR) 10 (2–22.8) 13 (3–23)
Min - Max 0–123 0–123
OAC VKA or NOAC 186 (23.1%) 323 (42.8%) <.01a
VKA 182 (22.6%) 188 (24.9%) .29a
Rivaroxaban 0 (0.0%) 121 (16.0%) <.01a
Dabigatran 5 (0.6%) 14 (1.9%) .03a
Apixaban 0 (0.0%) 10 (1.3%) <.01c
ASA (without additional OAC)d 123 (15.3%) 62 (8.2%) <.01a
consultation of cardiologist 125 (15.5%) 165 (21.9%) <.01a
CONTENT-Patients with diagnosis of atrial fibrillation, which were registered only once, either in 2011 (group A) or in 2014 (group B). OAC oral anticoagulation,
VKA vitamin-k antagonists, NOAC novel oral anticoagulation, ASA Acetylsalicylic acid
aChi2-test, bMann-Whitney-U-test, cFisher’s exact test
dIndication for ASA (100 mg), such as peripheral vascular disease or post-stroke or post-myocardial infarction or else and either as primary or secondary
prophylaxis, could not clearly be stated
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primary care are rare, but it can be assumed that low life
expectancy, high risk of falling and bleeding, as well as
frailty are reasons to refrain from prescribing OAC in
AF. This contrasts with views of experts, such as the
European-Primary-Care-Cardiovascular-Society
(EPCCS), who claim that a high bleeding-risk-score
(such as HAS-BLED, ORBIT or ABC) should generally
not result in withholding OAC [6, 22].
Our data showed a significant increase in the
prescription-rate of OAC in AF before and after
market-share of NOAC. The design of our study does
not allow causal attribution so it is not known if this in-
crease might be caused by an alternative medication to
VKA general practitioners had awaited, by an update
and implementation of guidelines on non-valvular AF,
by a generous promotion of NOAC or a mix of it all.
Table 2 Patient characteristics over time
GROUP C (2011) GROUP C (2014) p-value
patients (n) total 1083 n/a
gender (%) male 584 (53.9%) n/a
female 470 (43.4%)
undetermined 29 (2.7%)
age (years) Median (IQR) 75 (68–81) 78 (71–84) n/a
Min – Max 24–93 27–96
< 65 200 (18.5%) 145 (13.4%)
65–74 321 (29.6%) 241 (22.3%)
≥75 562 (51.9%) 697 (64.4%)
additional diagnosis patients With at least 1 1003 (92.6%) 986 (91.0%) .13a
renal insufficiency 61 (5.6%) 65 (6.0%) .77a
coagulopathy 17 (1.6%) 17 (1.6%) 1.0a
intracranial bleeding 4 (0.4%) 5 (0.5%) 1.0a
epistaxis 21 (1.9%) 14 (1.3%) .30a
gastrointestinal bleeding 13 (1.2%) 17 (1.6%) .59a
stroke 33 (3.0%) 28 (2.6%) .58a
CHA2DS2-VASC: 0 92 (8.5%) 59 (5.4%) <.01
a
1 100 (9.2%) 87 (8.0%)
≥2 884 (81.6) 908 (83.8%)
not computable 7 (0.6%) 29 (2.7%) n/a
prescriptions (per year) total 1056 (97.5%) 1064 (98.2%) n/a
M (SD) 19.4 (14.6) 22.6 (16.5) <.01b
Min - Max 1–118 1–115
all patients including those without prescription <.01b
M (SD) 18.8 (14.8) 22.0 (16.7)
Min - Max 0–118 0–115
OAC1 VKA or NOAC 382 (35.3%) 600 (55.4%) <.01a
VKA 373 (34.4%) 387 (35.7%) .41a
Rivaroxaban 3 (0.3%) 181 (16.7%) <.01a
Dabigatran 7 (0.6%) 23 (2.1%) <.01a
Apixaban none 28 (2.6%) n/c
ASA (without additional OAC)2 136 (12.6%) 97 (9.0%) <.01a
consultation of cardiologist 245 (22.6%) 262 (24.2%) .32a
CONTENT-Patients with diagnosis of atrial fibrillation, which were observed over time including data from 2011 and follow-up in 2014 (group C). OAC = oral
anticoagulation, VKA = vitamin-k antagonists, NOAC = novel oral anticoagulation, ASA = Acetylsalicylic acid
1Different prescriptions per year such as VKA and NOAC or NOAC and NOAC was possible (n = 29)
2Indication for ASA (100 mg), such as peripheral vascular disease or post-stroke or post-myocardial infarction or else and either as primary or secondary
prophylaxis, could not clearly be stated
aMcNemar test, b t-test for dependent samples
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We showed majority of patients with AF and OAC in
2014 received VKA. Until today, whether NOAC or
VKA are safer and/or more effective in prophylaxis of
stroke in non-valvular AF remains a key-point of
experts-discussions as well as on-going trials [23]. In
summary, there is a need for further research into the
determinants of prescribing OAC in patients with AF
in primary care.
Strengths and limitations
Strengths of this study are large number of primary care
practices and reasonably high quality of patient records.
Participating practices had university affiliation, which is
associated with higher involvement in continuous medical
education. It may be noted that in the German health care
system documentation of AF (ICD48.*) must be con-
firmed by Electrocardiogram (ECG), as recommend in up-
dated guidelines on AF [6]. All participating practices
were well experienced in daily use of ECG, but we could
not independently verify the recorded diagnosis of AF.
Secondly, due to routine data out of patient charts under-
reporting of AF (ICD48.*) as well as comorbidities and
follow-up might be possible [24]. However, we focussed
on the prescriptions of OAC for patients with AF and
those with undocumented AF cannot be considered for
treatment. Finally, we did not know which patients did
not receive anticoagulants due to (relative or absolute)
contraindications such as liver dysfunction.
Conclusions
We aimed to document prescription-rates of OAC
(VKA and NOAC) in primary care patients with AF in
Germany before and after broad market-share of NOAC
and to explore whether known patients with AF were
switched onto NOAC. In summary, our study showed a
significant increase of OAC over time, which is fosterer
by the use of NOAC but with a stable rate of VKA and a
sharp decrease of ASA. Patients on VKA are rarely
switched to NOAC, but new patients with AF are more
likely to receive NOAC. In 2014, 45% of patients with
CHA2DS2-VASc-Score ≥ 2 were not prescribed OAC,
suggesting room for improvement. Further research is
needed to identify factors contributing to this.
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